The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program
PD-L1 is a proven biomarker for patient response to KEYTRUDA ® (pembrolizumab) in NSCLC (PD-L1 IHC 22C3 pharmDx [package insert], 2019). Review how to evaluate and score PD-L1 …
The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program
PD-L1 是经证实，可以用于预测 NSCLC 患者是否能从 KEYTRUDA ® （帕博利珠单抗）治疗获益的生物标记物，本课程将引领您一起，了解如何对以 PD-L1 IHC 22C3 pharmDx 进行 PD-L1 …
The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program
本教程旨在回顾并介绍如何正确使用 PD-L1 检测试剂盒（免疫组织化学法）和 联合阳性评分 (CPS) 对 PD-L1 表达进行判读与评分。 Dako PD-L1 检测试剂盒（免疫组织化学法）判读培训 …
The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program
The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program PD-L1 is a critical biomarker for the only FDA-approved anti-PD-1 monotherapy to treat cervical cancer patients. Review …
The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program
PD-L1 is a critical biomarker for a breakthrough therapy for NSCLC patients. Get educated on how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx. The Dako PD …
The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program
Review how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS). The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training …
The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program
PD-L1 is a proven biomarker for patient response to KEYTRUDA ® (pembrolizumab) in triple-negative breast cancer (TNBC) (PD-L1 IHC 22C3 pharmDx [Instructions for Use], 2020). …
PD-L1 IHC 22C3 pharmDx「ダコ」検査の染色結果判定トレーニン …
PD-L1 IHC 22C3 pharmDx「ダコ」は、抗 PD-L1マウスモノクローナル抗体（Clone 22C3）を用いた免疫組織化学染色法を原理としたアッセイキットです。
The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program
食道扁平上皮癌検体において PD-L1 IHC 22C3 pharmDx「ダコ」を用いた際の PD-L1 発現の評価およびスコアリング方法について確認します。
Dako - Registration
NOTE: All fields are required Function Department Market Title First Name Last Name Company/Organization Address City Postal Code Country Phone Number Email address …